Surveillance of Rotavirus Gastroenteritis
NCT02900703 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 9000
Last updated 2016-09-14
Summary
* Epidemiological studies have shown the diversity of resistance genotypes and the evolution of their prevalence in the paediatric population. This large study conducted in a context of very low vaccination coverage will generate more precise data on the natural epidemiological evolution of rotavirus, notably the G9 genotype, which has appeared relatively recently.
* This study will allow us to identify and document rare or unusual strains of human or animal origin. The complete genetic characterization of these strains will also make it possible to study their ability to recombine and to assess the risk of emergence. Among these still rare strains, the investigators are particularly monitoring G12 rotavirus, whose ability to recombine raises the risk of emergence.
* For at least one of the centres taking part in the study, the paediatric population studied will be given strong vaccination coverage. It will be extremely interesting to compare the results obtained in the vaccinated population with non-vaccinated children to assess the impact of this vaccination on the distribution of rotavirus genotypes
Conditions
Interventions
- BIOLOGICAL
-
stool samples
Sponsors & Collaborators
-
Centre Hospitalier Universitaire Dijon
lead OTHER
Eligibility
- Max Age
- 5 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-02-28
- Primary Completion
- 2017-02-28
Countries
- France
Study Locations
More Related Trials
-
To Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK's Oral Human Rotavirus Vaccine in Pre-Term Infants
NCT00420745 ·Status: COMPLETED ·Phase: PHASE3
-
Intussusception Surveillance After Rotarix Introduction in Mexico
NCT00595205 ·Status: COMPLETED
-
A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants.
NCT00140673 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months
NCT00385320 ·Status: COMPLETED ·Phase: PHASE2
-
Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitution Without Buffering Agent; & Evaluate the Immunogenicity, Reactogenicity & Safety of the Vaccine After Storage for 7 d at 37°C Following 2 Doses in Healthy Infants
NCT00169455 ·Status: COMPLETED ·Phase: PHASE3
-
Study of 2 Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis
NCT00134732 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Reactogenicity and Immunogenicity of Heat-stable Rotavirus Vaccine (HSRV) in Adults and Infants
NCT02728869 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants
NCT00197210 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.
NCT00729001 ·Status: COMPLETED ·Phase: PHASE2
-
Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants
NCT00241644 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States
NCT00875641 ·Status: COMPLETED
-
Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali
NCT02286895 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers
NCT05621655 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
TyVECO: Surveillance Protocol
NCT05562102 ·Status: UNKNOWN
-
Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean Infants
NCT00969228 ·Status: COMPLETED ·Phase: PHASE4
-
Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.
NCT00420316 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants
NCT00750893 ·Status: COMPLETED
-
Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine in Healthy Infants
NCT01107587 ·Status: COMPLETED ·Phase: PHASE1
-
Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infants in India
NCT00289172 ·Status: COMPLETED ·Phase: PHASE3
-
Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants
NCT00425737 ·Status: COMPLETED ·Phase: PHASE2
-
Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula Polymorpha)
NCT05916326 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants
NCT00779779 ·Status: COMPLETED
-
V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)
NCT00258154 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks
NCT06025695 ·Status: COMPLETED ·Phase: PHASE3
-
A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine).
NCT00382772 ·Status: COMPLETED ·Phase: PHASE3